This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul Creighton Hobar, MD; Ronald C. Jones, MD; Jeffrey Schouten, MD; A. Marilyn Leitch, MD; Fred Hendler, MD

Arch Surg. 1988;123(8):951-955.

Abstract
• Forty patients with 41 locally advanced breast lesions at stages IIIA and IIIB and the inflammatory stage were treated with combined-modality therapy from July 1980 to August 1985. Treatment included induction chemotherapy consisting of three cycles of fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by mastectomy in those patients whose lesions were operable (n=28), and resumption of chemotherapy. Nine patients received postoperative radiation therapy. The mean follow-up was 34 months. Greater than 50% reduction in tumor size was achieved in 72% of patients after three cycles of chemotherapy. Overall, local control was achieved in 85% of patients with 59% survival and 53% disease-free survival, while 10% of patients developed local recurrences. Excluding lymphedema of the upper extremity (n=2) and inflammatory carcinomas (n=4), local control was achieved in 96% of patients, with 75% survival and 68% disease-free survival, while 4% of patients developed local recurrences. The rate of disease-free survival was 71% in patients with partial response to chemotherapy, contrasted with 43% in patients who did not respond or only minimally responded to chemotherapy. Actuarial five-year survival, based on life-table analysis, was calculated to be 46% for the group overall, 58% for the group excluding lymphedema of the upper extremity and inflammatory carcinoma, and 56% for the 28 patients undergoing mastectomy.

(Arch Surg 1988;123:951-955)

Author Affiliations
From the Departments of Plastic Surgery (Dr Hobar) and Surgery (Dr Leitch), University of Texas Health Science Center, and the Department of Surgery, Baylor University Medical Center (Dr Jones), Dallas; the Department of Surgery, Hawaii Permanente Medical Group, Honolulu (Dr Schouten); and the Division of Oncology, Department of Medicine, University of Louisville (Dr Hendler).

Footnotes
Accepted for publication March 30, 1988.

Read before the 95th Annual Meeting of the Western Surgical Association, Dallas, Nov 17, 1987.

Reprint requests to Baylor University Medical Center, 3500 Gaston Ave, Dallas, TX 75246 (Dr Jones).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
Moon et al.
Ann Oncol 2005;16:1778-1785.
ABSTRACT | FULL TEXT  

Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study
Delille et al.
Radiology 2003;228:63-69.
ABSTRACT | FULL TEXT  

Locally Advanced Breast Cancer
Valero et al.
The Oncologist 1996;1:8-17.
ABSTRACT | FULL TEXT